IKT — Inhibikase Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Inhibikase Therapeutics Granted Pre-NDA Meeting With The FDA For IkT-001Pro
Brief: Inhibikase Therapeutics Receives FDA Orphan Drug Designation For The Treatment Of Multiple System Atrophy
Brief: Inhibikase Therapeutics Announces Development Of Novel Formulation Of Risvodetinib
Brief: Inhibikase Therapeutics Initiates Development Of Second Generation C-Abl Inhibitors And Names Ikt-148009 As Risvodetinib
Brief: Inhibikase Therapeutics Completes 501 Bioequivalence Study Of Ikt-001Pro
Inhibikase Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Inhibikase Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Inhibikase Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Regains Compliance With Nasdaq Listing Requirements
Inhibikase Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Inhibikase Therapeutics Reports First Quarter Financial Results And Highlights Recent Period Activity
Inhibikase Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Provides Safety And Functional Update On Its Phase 1/1B 101 Trial And Its Phase 2 Ikt-148009 201 Trial In Parkinson's Disease
H.C. Wainwright starts coverage on Inhibikase with 'buy', shares rise
Inhibikase Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Inhibikase Therapeutics Reports 2022 Loss Per Share Of $0.72
Inhibikase Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Provides Interim Update On '501' Bioequivalence Study Of IkT-001Pro
Brief: Inhibikase Therapeutics Inc - Does Not Hold Cash Deposits Or Lines Of Credit With Svb, And Does Not Otherwise Have A Business Relationship With Svb